Credit Suisse’s Compass Therapeutics CMPX Stock Holding History

Credit Suisse’s Portfolio CMPX Stock Details CMPX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-73,368	Closed	-$145K	–	3077
2023 Q3	$145K	Sell	73,368 -4,056	-5%	-$10K	﹤0.01%	3068
2023 Q2	$246K	Buy	77,424 +19,265	+33%	+$60.5K	﹤0.01%	3059
2023 Q1	$190K	Buy	+58,159	New	+$228K	﹤0.01%	3125

Other funds holding CMPX

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Credit Suisse's CMPX Position: Q4 2023 in Review

Credit Suisse sold out of Compass Therapeutics (CMPX) in Q4 2023, closing a stake of 73,368 shares — an estimated $145K sold.

Credit Suisse first reported a position in CMPX in Q1 2023 and held it in 3 quarters. The position peaked at $246K in Q2 2023. 77 funds tracked by Wall St. Rank hold CMPX as of Q4 2023.

Credit Suisse reported no remaining Compass Therapeutics position as of Q4 2023 after selling out during the quarter.
Credit Suisse sold 73,368 Compass Therapeutics shares in Q4 2023, an estimated $145K.
Credit Suisse first reported a position in Compass Therapeutics in Q1 2023 and held it in 3 quarters.
Credit Suisse's Compass Therapeutics position peaked at $246K in Q2 2023.
77 funds tracked by Wall St. Rank held Compass Therapeutics as of Q4 2023.

Based on Credit Suisse's 13F filing for Q4 2023, filed 8 Feb 2024.